Original Article

Regulatory Network Analysis to Reveal Important miRNAs and Genes in Non-Small Cell Lung Cancer

Xingni Zhou, M.M.[1#], Zhenghua Zhang, M.M.[2#], Xiaohua Liang, M.D.[1*]

1. Department of Oncology, Huashan Hospital of Fudan University, Shanghai, China
2. Department of Clinical Oncology, Jing'an District Centre Hospital of Shanghai (Huashan Hospital, Fudan University, Jing'an Branch), Shanghai, China

#The first two authors equally contributed to this work.

*Corresponding Address: Department of Oncology, Huashan Hospital of Fudan University, No.12 the Middle Wu Lu Mu Qi Road, Shanghai, China
Email: Liangxiaohuahh@163.com

Abstract
Objective: Lung cancer has high incidence and mortality rate, and non-small cell lung cancer (NSCLC) takes up approximately 85% of lung cancer cases. This study is aimed to reveal miRNAs and genes involved in the mechanisms of NSCLC.

Materials and Methods: In this retrospective study, GSE21933 (21 NSCLC samples and 21 normal samples), GSE27262 (25 NSCLC samples and 25 normal samples), GSE43458 (40 NSCLC samples and 30 normal samples) and GSE74706 (18 NSCLC samples and 18 normal samples) were searched from gene expression omnibus (GEO) database. The differentially expressed genes (DEGs) were screened from the four microarray datasets using MetaDE package, and then conducted with functional annotation using DAVID tool. Afterwards, protein-protein interaction (PPI) network and module analyses were carried out using Cytoscape software. Based on miR2Disease and Mirwalk2 databases, microRNAs (miRNAs)-DEG pairs were selected. Finally, Cytoscape software was applied to construct miRNA-DEG regulatory network.

Results: Totally, 727 DEGs (382 up-regulated and 345 down-regulated) had the same expression trends in all of the four microarray datasets. In the PPI network, TP53 and FOS could interact with each other and they were among the top 10 nodes. Besides, five network modules were found. After construction of the miRNA-gene network, top 10 miRNAs (such as *hsa-miR-16-5p, hsa-let-7b-5p, hsa-miR-15a-5p, hsa-miR-15b-5p, hsa-let-7a-5p* and *hsa-miR-34a-5p*) and genes (such as *HMGA1, BTG2, SOD2* and *TP53*) were selected.

Conclusion: These miRNAs and genes might contribute to the pathogenesis of NSCLC.

Keywords: Meta-Analysis, microRNA, Non-Small Cell Lung Cancer, Protein Interaction, Regulatory Network

Introduction

Lung cancer is a common tumor which has globally high incidence and mortality rate with 1.82 million newly diagnosed cases and 1.56 million death cases in 2012 (1). Lung cancer is comprised of small cell lung cancer (SCLC) and non-SCLC (NSCLC), among which NSCLC takes up approximately 85% of lung cancer cases (2). Tobacco smoking is the primary inducement for lung cancer, and other risk factors are air-pollution, radon, asbestos and chemical exposure (3). NSCLC mainly contains squamous cell carcinoma, adenocarcinoma and large cell carcinoma, while nearly half of NSCLC cases are non-squamous cell carcinoma (4). NSCLC is less sensitive to chemotherapy in comparison to SCLC, and it is usually treated by surgical resection (5). Therefore, investigating pathogenesis of NSCLC is of great significance.

Previous study found that fibroblast growth factor receptor 1 (*FGFR1*) amplification is common in NSCLC and it might be utilized as a therapeutic target for inhibiting tumor cell growth (6, 7). Overexpressed lysine specific demethylase 1 (*LSD1*) can lead to poor prognosis of NSCLC patients, which also enhances cell proliferation, invasion and migration (8). Transcriptional co-activation with PDZ-binding motif (*TAZ*) is found to be an oncogene and plays a tumorigenic role in NSCLC, and thus *TAZ* serves as a potential diagnostic, therapeutic and prognostic target for the disease (9). *microRNA-21* (*miR-21*) is up-regulated in NSCLC tissues in comparison with normal tissues, which can negatively regulate phosphatase and tensin homolog (*PTEN*) expression. It contributes to the growth and invasion of tumor cells (10). *miR-451* expression is significantly related to pathological stage, tumor differentiation and lymph-node metastasis, and it mediates the survival of NSCLC

patients via down-regulating ras-related protein 14 (*RAB14*) (11). Although the above genes and miRNAs are considered to be correlated with NSCLC, the mechanisms of the disease have not been studied and reported comprehensively.

Meta-analysis for multiple datasets can improve statistical ability and identify more reliable differentially expressed genes (DEGs) (12, 13). In the current study, several microarray data of NSCLC were downloaded and conducted with meta-analysis. Subsequently, enrichment analysis and network analysis were carried out to select the key genes and miRNAs for NSCLC. Ultimately, it was concluded that the identified genes and miRNAs might be involved in the mechanisms of NSCLC and they may serve as promising targets for treatment of the disease.

Materials and Methods

Expression profile data

In this retrospective study, the expression profiles involving both NSCLC and normal samples were searched from gene expression omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/). Finally, the raw data and platform annotation files under GSE21933 (21 NSCLC and 21 normal samples; platform: GPL6254 Phalanx Human OneArray), GSE27262 (25 NSCLC and 25 normal samples; platform: GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array), GSE43458 (40 NSCLC and 30 normal samples; platform: GPL6244 [HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array) and GSE74706 (18 NSCLC and 18 normal samples; platform: GPL13497 Agilent-026652 Whole Human Genome Microarray 4x44K v2) were extracted.

Data preprocessing

For the raw data, background correction and normalization were conducted by the Affy package of R software (http://www.bioconductor.org/packages/release/bioc/html/affy.html) (14). Combined with the platform annotation files, probe IDs were transformed into gene symbols and the probes which have no matching gene symbols were removed. Expression value of the gene matched with many probes was acquired by calculating the average value of the probes.

Meta-analysis

Using the MetaDE package in R software (https://cran.r-project.org/web/packages/MetaDE/) (15), DEGs were screened from the four microarray datasets. In detail, heterogeneity test was carried out for the expression values of each gene under different experimental platforms. The tau2=0 (estimated amount

of residual heterogeneity) and Qpval>0.05 (P values for the test of heterogeneity) were the cut-off criteria of homogeneous data set. Then, differential expression analysis was conducted for NSCLC and normal samples. Using Benjamini-Hochberg method (16), the P values were corrected to obtain false discovery rates (FDRs). Genes with tau2=0, Qpval>0.05 and FDR<0.05 were defined as DEGs. Furthermore, log2 fold change (FC) values of the DEGs were calculated. The DEGs with log2FC>0 in all of the four datasets were up-regulated genes in NSCLC samples, and the DEGs with log2FC<0 in all of the four datasets were down-regulated genes.

Enrichment analysis

Gene ontology (GO; http://www.geneontology.org) describes the purposes of gene products from molecular function (MF), biological process (BP), and cellular component (CC) aspects (17). The Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.ad.jp/kegg) is a reference database for annotating genes or proteins (18). Based on the database for annotation, visualization and integrated discovery (DAVID; https://david.ncifcrf.gov/, version 6.8) tool, GO and KEGG analyses for the selected DEGs were conducted. The terms involving two or more genes and having P<0.05 were considered significant results.

Protein-protein interaction network construction

Search tool for the retrieval of interacting genes (STRING; http://string-db.org/, version 10.0) integrates the protein-protein interactions (PPIs) of various organisms. With medium confidence > 4, as the threshold, PPIs were predicted for the DEGs using the STRING database (19). Next, PPI network was built by Cytoscape software (http://www.cytoscape.org, version 3.2.0). Moreover, degree centrality of the network nodes was analyzed, and those with higher degrees were taken as key nodes. Additionally, molecular complex detection (MCODE) plug-in in Cytoscape software (20) was applied for module analysis to identify the significant modules.

Construction of miRNA-DEG regulatory network

The miR2Disease (http://www.mir2disease.org/) is a database, containing dysregulated miRNAs implicated in multiple diseases. The miRNAs related to NSCLC were searched from miR2Disease database (21). Then, the verified targets of the NSCLC-associated miRNAs were obtained from Mirwalk2 database (http://zmf.umm.uni-heidelberg.de/mirwalk2) (22). Through getting the intersection of the targets and the DEGs, the miRNA-DEG regulatory relationships were selected. Finally, miRNA-gene regulatory network was built using Cytoscape software (20).

Results

Meta-analysis and enrichment analysis

There were a total of 749 dysregulated genes in NSCLC, compared to normal samples. Among these genes, 727 DEGs (382 up-regulated and 345 down-regulated) had the same expression trends in all of the four microarray datasets. The DEGs were enriched in multiple GO and KEGG terms, indicating the potential functions of the DEGs. Top five terms involving the up-regulated and down-regulated genes are respectively shown in Figure 1A and 1B.

Protein-protein interaction network analysis

A PPI network was built for the identified DEGs, involving 606 nodes and 2246 edges (Fig.S1) (See Supplementary Online Information at www.celljournal. org). After arranging the node degrees in descending order, tumor protein p53 (TP53, up, degree=109), mitogen-activated protein kinase 3 (MAPK3, down, degree=55), RNA polymerase II subunit B (POLR2B, up, degree=50), FBJ osteosarcoma oncogene (FOS, down, degree=49), integrin alpha 2 (ITGA2, up, degree=48), mechanistic target of rapamycin kinase (MTOR, up, degree=46), early growth response 1 (EGR1, down, degree=39), eukaryotic elongation factor 2 (EEF2, down, degree=34), ISG15 ubiquitin-like modifier (ISG15, up, degree=33), and ABL proto-oncogene 1 (ABL1, down, degree=33) were among the top 10 nodes. Importantly, TP53 could interact with FOS in the PPI network, suggesting that TP53 might act in NSCLC via interacting with FOS.

Besides, five significant network modules (module a: 13 nodes and 77 edges; module b: 35 nodes and 110 edges; module c: six nodes and 15 edges; module d: six nodes and 15 edges; module e: 22 nodes and 45 edges) were selected (Fig.2). KEGG pathway enrichment analysis was conducted for the nodes in each module. Especially, Spliceosome (module a, P=1.53E-05), HTLV-I infection (module b, P=4.62E-04), Basal transcription (module c, P=1.24E-04), Ribosome (module d, P=1.44E-07), and Epstein-Barr virus (module e, P=9.95E-04) were enriched for the module nodes (Table 1).

Construction of miRNA-DEG regulatory network

From miR2Disease database, a total of 27 NSCLC-associated miRNAs was obtained. There were 15421 verified miRNA-target interactions, involving 27 miRNA in Mirwalk2 database. After selecting miRNA-DEG pairs, miRNA-gene regulatory network (involving 358 nodes and 658 edges) was visualized (Fig.S2) (See Supplementary Online Information at www.celljournal.org). According to node degrees, top 10 miRNAs (such as *hsa-miR-16-5p*, *hsa-let-7b-5p*, *hsa-miR-15a-5p*, *hsa-miR-15b-5p*, *hsa-let-7a-5p* and *hsa-miR-34a-5p*) and genes (such as high mobility group AT-hook 1, *HMGA1*; BTG family, member 2, *BTG2*; superoxide dismutase 2, *SOD2*; and *TP53*) were selected and listed in Table 2, while they might be critical for development of NSCLC (Fig.3).


Fig.1: The results of enrichment analysis for the differentially expressed genes. **A.** Top five terms enriched for the up-regulated genes and **B.** Top five terms enriched for the down-regulated genes. The horizontal and vertical axes represent name of the enriched term and number of the genes involved in each term, respectively. BP; Biological process, CC; Cellular component, and MF; Molecular function.

Fig.2: The significant modules identified from protein-protein interaction (PPI) network. **A.** The significant module a, **B.** The significant module b, **C.** The significant module c, **D.** The significant module d, and **E.** The significant module e. Red circles and green prismatic represent up-regulated genes and down-regulated genes, respectively.

Table 1: Pathways enriched for the nodes in module a, b, c, d and e

Module	Pathway ID	Pathway name	Count	P value	Genes
a	hsa03040	Spliceosome	5	1.53E-05	*PRPF8, SNRNP200, SNRPA, SNRPD2, SF3B2*
	hsa03020	RNA polymerase	3	7.33E-04	*POLR2G, POLR2I, POLR2B*
	hsa00240	Pyrimidine metabolism	3	7.54E-03	*POLR2G, POLR2I, POLR2B*
	hsa00230	Purine metabolism	3	2.06E-02	*POLR2G, POLR2I, POLR2B*
	hsa05169	Epstein-Barr virus infection	3	2.38E-02	*POLR2G, POLR2I, POLR2B*
	hsa05016	Huntington's disease	3	2.43E-02	*POLR2G, POLR2I, POLR2B*
b	hsa05166	HTLV-I infection	7	4.62E-04	*EGR1, FOS, ETS1, TP53, NFKBIA, TCF3, NFATC1*
	hsa04660	T cell receptor signaling pathway	5	7.24E-04	*PTPRC, FOS, MAPK3, NFKBIA, NFATC1*
	hsa05161	Hepatitis B	5	2.57E-03	*FOS, MAPK3, TP53, NFKBIA, NFATC1*
	hsa04662	B cell receptor signaling pathway	4	2.61E-03	*FOS, MAPK3, NFKBIA, NFATC1*
	hsa04010	MAPK signaling pathway	6	3.22E-03	*FOS, MAPK3, TP53, DDIT3, NFATC1, DUSP6*
	hsa05133	Pertussis	4	3.31E-03	*FOS, IRF8, MAPK3, PYCARD*
	hsa05215	Prostate cancer	4	5.19E-03	*MAPK3, TP53, NFKBIA, MTOR*
	hsa04668	TNF signaling pathway	4	8.70E-03	*FOS, MAPK3, EDN1, NFKBIA*
	hsa04151	PI3K-Akt signaling pathway	6	1.15E-02	*MAPK3, COL3A1, COL6A3, TP53, ITGB4, MTOR*
	hsa04380	Osteoclast differentiation	4	1.54E-02	*FOS, MAPK3, NFKBIA, NFATC1*
	hsa04621	NOD-like receptor signaling pathway	3	2.06E-02	*MAPK3, PYCARD, NFKBIA*
	hsa04921	Oxytocin signaling pathway	4	2.53E-02	*FOS, PRKAG1, MAPK3, NFATC1*
	hsa05210	Colorectal cancer	3	2.58E-02	*FOS, MAPK3, TP53*
	hsa05230	Central carbon metabolism in cancer	3	2.73E-02	*MAPK3, TP53, MTOR*
	hsa05214	Glioma	3	2.81E-02	*MAPK3, TP53, MTOR*
	hsa04920	Adipocytokine signaling pathway	3	3.23E-02	*PRKAG1, NFKBIA, MTOR*
	hsa05140	Leishmaniasis	3	3.31E-02	*FOS, MAPK3, NFKBIA*
	hsa05220	Chronic myeloid leukemia	3	3.40E-02	*MAPK3, TP53, NFKBIA*
	hsa05132	Salmonella infection	3	4.40E-02	*FOS, MAPK3, PYCARD*
	hsa04024	cAMP signaling pathway	4	4.49E-02	*FOS, MAPK3, NFKBIA, NFATC1*
	hsa04512	ECM-receptor interaction	3	4.79E-02	*COL3A1, COL6A3, ITGB4*
	hsa04510	Focal adhesion	4	4.95E-02	*MAPK3, COL3A1, COL6A3, ITGB4*
c	hsa03022	Basal transcription factors	3	1.24E-04	*CCNH, ERCC3, GTF2B*
	hsa03420	Nucleotide excision repair	2	2.03E-02	*CCNH, ERCC3*
d	hsa03010	Ribosome	5	1.44E-07	*MRPL24, MRPL1, MRPL13, RPL15, RPL27*
e	hsa05169	Epstein-Barr virus infection	5	9.95E-04	*POLR3K, SPI1, CD40, ENTPD1, POLR3E*
	hsa00240	Pyrimidine metabolism	4	1.93E-03	*POLR3K, DPYD, ENTPD1, POLR3E*
	hsa00230	Purine metabolism	4	8.49E-03	*POLR3K, AK3, ENTPD1, POLR3E*
	hsa04620	Toll-like receptor signaling pathway	3	2.73E-02	*IRAK4, TLR1, CD40*

ID; Identification, HTLV; Human T-lymphotropic virus type 1, TNF; Tumour-necrosis factor, NOD; Nucleotide oligomerization domain, and ECM; Extracellular matrix.

Fig.3: miRNAs-gene regulatory network containing the top 10 miRNAs. Red circles, green prismatic and yellow triangles represent up-regulated genes, down-regulated genes and miRNAs, respectively.

Table 2: Top 10 miRNAs and genes in the miRNA-gene regulatory network

miRNA	Degree	Gene	Degree
hsa-miR-16-5p	89	*HMGA1*	11
hsa-let-7b-5p	84	*BAZ2A*	9
hsa-miR-15a-5p	44	*CALU*	9
hsa-miR-15b-5p	41	*BTG2*	8
hsa-let-7a-5p	40	*SOD2*	8
hsa-miR-34a-5p	37	*TP53*	7
hsa-miR-21-5p	33	*UBN2*	7
hsa-miR-222-3p	24	*CBX5*	6
hsa-miR-221-3p	23	*ITGA2*	6
hsa-miR-372-3p	23	*SLC10A7*	6

Discussion

To investigate the pathogenesis of lung tumorigenesis, Lo et al. (23) identify the differential and common chromosomal imbalance regions among Asian and Caucasian patients with lung cancer through analyzing the microarray dataset GSE21933. Using the dataset GSE27262, Wei et al. (24) explored the roles of protein arginine methyltransferase 5 (*PRMT5*) in the oncogenesis of lung cancer, and revealed cell-transforming activity of *PRMT5* and relevant mechanisms. Kabbout et al. (25) deposited and analyzed the microarray dataset GSE43458 to investigate the functions of *ETS2* in development of lung cancer, finding that *ETS2* acts as a tumor suppressor in NSCLC by suppressing *MET* proto-oncogene. Via analyzing the expression profile GSE74706, Marwitz et al. (26) found that reduced bone morphogenetic protein and activin membrane-bound inhibitor (*BAMBI*) contributes to the invasiveness of NSCLC and TGF-β signaling serves a candidate target for treating the disease. Nevertheless, the above studies have not conducted comprehensive bioinformatics analyses to identify the molecular mechanisms of NSCLC. In the present study, various bioinformatics methods were utilized to select the key genes and miRNAs for NSCLC. In the PPI network, TP53 and FOS were among the top 10 nodes. From the miRNA-gene regulatory network, the top 10 miRNAs (such as *hsa-miR-16-5p*, *hsa-let-7b-5p*, *hsa-miR-15a-5p*, *hsa-miR-15b-5p*, *hsa-let-7a-5p* and *hsa-miR-34a-5p*) and genes (such as *HMGA1*, *BTG2*, *SOD2* and *TP53*) were selected.

As a pivotal inhibitor of tumor-suppressor *p53*, up-regulated *iASPP* (inhibitory member of the apoptosis-stimulating protein of p53 family) mediates tumor cell proliferation and motility, and it serves as a promising target for treatment of lung cancer (27). Tumor suppressor *miR-34a* regulates some molecules involved in cell survival pathways, and p53/*miR-34a* regulatory axis may play important roles in sensitizing NSCLC cells (28). Through c-Fos/c-Jun pathway, interleukin ⅴ (ILⅴ-) /ILⅴ-R enhance vascular endothelial growth factor-D (*VEGF-D*) expression and contribute to lymphangiogenesis in lung cancer (29). Via increasing protein expression of c-Fos and adaptor protein complex 1 (AP-1)/DNA binding, fibronectin (*FN*) promotes matrix metalloproteinase-9 (*MMP-9*) expression and accelerates NSCLC cell invasion and metastasis (30). TP53 could interact with FOS in the PPI network, suggesting that *TP53* and *FOS* might be involved in the pathogenesis of NSCLC through interacting with each other.

HMGA1 has higher expression in NSCLC tissues in comparison with normal lung tissues, which functions in development and prognosis of NSCLC (31). *HMGA1* was found to play a critical role in transformation through up-regulating *MMP-2* in large-cell lung carcinoma (32). *BTG2* overexpression may inhibit *MMP-1*, *MMP-2* and cyclin D1 (*CCND1*) expression in lung cancer A549 cell line, and it also has potential of suppressing tumor cell proliferation, growth and invasiveness (33, 34). By promoting oxidative stress and SOD2 protein expression, simvastatin suppresses proliferation of lung A549 cells (35). These declared that *HMGA1*, *BTG2* and *SOD2* might play critical roles in the mechanisms of NSCLC.

Co-regulated *miR-15a/16* and *miR-34a* can synergistically arrest the cell cycle of NSCLC in an Rb-dependent manner (36). Down-regulated *let-7b* and *miR-126* may have anti-angiogenic effect and they significantly contribute to poor survival in the patients with lung cancer (37, 38). Overexpression of *miR-15b* can promote the cisplatin chemoresistance of lung adenocarcinoma cells by inhibiting the expression of phosphatidylethanolamine-binding protein 4 (*PEBP4*) (39). *Let-7a* is down-regulated in NSCLC tissues, NSCLC cells and NSCLC blood samples, indicating that *let-7a* may be used as a serologic marker for the disease (40). Therefore, *hsa-miR-16-5p*, *hsa-let-7b-5p*, *hsa-miR-15a-5p*, *hsa-miR-15b-5p*, *hsa-let-7a-5p* and *hsa-miR-34a-5p* might also function in NSCLC via targeting the DEGs.

Conclusion

727 DEGs had similar expression trends in all of the four microarray datasets. Besides, several miRNAs (including *hsa-miR-16-5p*, *hsa-let-7b-5p*, *hsa-miR-15a-5p*, *hsa-miR-15b-5p*, *hsa-let-7a-5p* and *hsa-miR-34a-5p*) and genes (including *HMGA1*, *BTG2*, *SOD2*, *FOS* and *TP53*) might associate with the pathogenesis of NSCLC and they might be applied for targeted therapy of NSCLC. However, no experimental research has been performed to confirm our results. Thus, more in-depth studies should be designed and implemented in the future.

Acknowledgement

Authors' Contributions

X.Z.; Contributed to the design of the research, acquisition of data, analysis and interpretation of data, statistical analysis and drafting the manuscript. Z.Z.; Contributed to the analysis and interpretation of data and statistical analysis. X.L.; Helped to draft this manuscript, analysis and interpretation of data and were responsible for overall supervision. All authors read and approved the final manuscript.

References

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. International Journal of Cancer Journal International Du Cancer. 2012; 136(5): E359–E86.
2. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN guidelines insights: non-small cell lung cancer, version 4. 2016. J Natl Compr Canc Netw. 2016; 14(3): 255-264.
3. Liu X, Conner H, Kobayashi T, Kim H, Wen F, Abe S, et al. Cigarette smoke extract induces DNA damage but not apoptosis in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2005; 33(2): 121-129.

4. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014; 14(8): 535-546.
5. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689): 446-454.
6. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive FGFR1 Amplification in human non-small cell lung cancer. PLoS One. 2011; 6(6): e20351.
7. Cihoric N, Savic S, Schneider S, Ackermann I, Bichselnaef M, Schmid RA, et al. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. Br J Cancer. 2014; 110(12): 2914-2922.
8. Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X, et al. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One. 2012; 7(4): e35065.
9. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene. 2011; 30(18): 2181-2186.
10. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010; 411(11-12): 846-852.
11. Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011; 30(23): 2644-2658.
12. Hong F, Breitling R. A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments. Bioinformatics. 2008; 24(3): 374-382.
13. Tseng GC, Ghosh D, Feingold E. Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res. 2012; 40(9): 3785-3799.
14. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3): 307-315.
15. Wang X, Kang DD, Shen K, Song C, Lu S, Chang LC, et al. An R package suite for microarray meta-analysis in quality control, differentially expressed gene analysis and pathway enrichment detection. Bioinformatics. 2012; 28(19): 2534-2536.
16. Moldvay J, Fábián K, Jäckel M, Németh Z, Bogos K, Furák J, et al. Claudin-1 protein expression is a good prognostic factor in non-small cell lung cancer, but only in squamous cell carcinoma cases. Pathol Oncol Res. 2017; 23(1): 151-156.
17. Liu W, Liu J, Rajapakse JC. Gene ontology enrichment improves performances of functional similarity of genes. Sci Rep. 2018; 8(1): 12100.
18. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. N Nucleic Acids Res. 2000; 28(1): 27-30.
19. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013; 41(Database issue): D808-D815.
20. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, et al. A travel guide to cytoscape plugins. Nat Methods. 2012; 9(11): 1069-1076.
21. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, et al. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res. 2009; 37(Database issue): D98-D104.
22. Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015; 12(8): 697.
23. Lo FY, Chang JW, Chang IS, Chen YJ, Hsu HS, Huang SF, et al. The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization. BMC Cancer. 2012; 12: 235.
24. Wei TY, Juan CC, Hisa JY, Su LJ, Lee YC, Chou HY, et al. Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade. Cancer Sci. 2012; 103(9): 1640-1650.
25. Kabbout M, Garcia MM, Fujimoto J, Liu DD, Woods D, Chow CW, et al. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res. 2013; 19(13): 3383-3395.
26. Marwitz S, Depner S, Dvornikov D, Merkle R, Szczygiel M, Müller-Decker K, et al. Downregulation of the TGF-β pseudoreceptor BAMBI in non-small cell lung cancer enhances TGF-β signaling and invasion. Cancer Res. 2016; 76(13): 3785-3801.
27. Chen J, Xie F, Zhang L, Jiang WG. iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway. BMC Cancer. 2010; 10: 694.
28. Chakraborty S, Mazumdar M, Mukherjee S, Bhattacharjee P, Adhikary A, Manna A, et al. Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells. FEBS Lett. 2014; 588(4): 549-559.
29. Ming J, Zhang Q, Qiu X, Wang E. Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: A mechanism of lymphangiogenesis in lung cancer. Eur J Cancer. 2009; 45(5): 866-873.
30. Han S, Ritzenthaler JD, Sitaraman SV, Roman J. Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells. J Biol Chem. 2006; 281(40): 29614-29624.
31. Zhang Z, Wang Q, Chen F, Liu J. Elevated expression of HMGA1 correlates with the malignant status and prognosis of non-small cell lung cancer. Tumour Biol. 2015; 36(2): 1213-1219.
32. Hillion J, Wood LJ, Mukherjee M, Bhattacharya R, Di Cello F, Kowalski J, et al. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res. 2009; 7(11): 1803-1812.
33. Wei S, Hao C, Li X, Zhao H, Chen J, Zhou Q. Effects of BTG2 on proliferation inhibition and anti-invasion in human lung cancer cells. Tumour Biol. 2012; 33(4): 1223-1230.
34. Sun Q, Hang M, Guo X, Shao W, Zeng G. Expression and significance of miRNA-21 and BTG2 in lung cancer. Tumour Biol. 2013; 34(6): 4017-4026.
35. Li Y, Fu J, Yuan X, Hu C. Simvastatin inhibits the proliferation of A549 lung cancer cells through oxidative stress and up-regulation of SOD2. Pharmazie. 2014; 69(8): 610-614.
36. Bandi N, Vassella E. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer. 2011; 10: 55.
37. Jusufović E, Rijavec M, Keser D, Korošec P, Sodja E, Iljazović E, et al. let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non-small-cell lung cancer. PLoS One. 2012;7(9):e45577.
38. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 2010; 29(11): 1580.
39. Zhao Z, Zhang L, Yao Q, Tao Z. miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells. Cancer Gene Ther. 2015; 22(3): 108-114.
40. Jeong HC, Kim EK, Lee JH, Lee JM, Yoo HN, Kim JK. Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients. Mol Med Rep. 2011; 4(2): 383-387.